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Breast cancer is one of the leading causes of cancer death 
in women mainly because the breast cancer cells frequently 
egress from the primary site and form secondary tumors in the 
distant organs including the bone and lung (1,2). Since 5-year 
survival of patients is dramatically reduced once the metastatic 
tumors are established (2), it is necessary to understand the 
mechanisms behind the metastatic tumor expansion in order 
to improve the outcome of breast cancer patients. 
It is now widely recognized that tumor infiltrating 
immune cells, especially tumor-associated macrophages 
(TAMs) promote the metastasis of solid tumors including 
breast cancer (3,4). Several mouse studies indicate that 
TAMs in the primary mammary tumors promote tumor 
angiogenesis, invasion, and intravasation, which promote 
tumor cell egress from the primary site (5-7). It is also 
reported that a distinct population of TAMs in the 
metastatic tumors, called metastasis-associated macrophages 
(MAMs), promote extravasation of circulating cancer 
cells as well as their survival and persistent growth in the 
metastatic site (8-11). Therefore, it has been suggested that 
targeting TAMs or MAMs can be a novel strategy to block 
the lethal metastasis formation and prolong the survival of 
patients with metastatic diseases (12).
It is well known that macrophages possess remarkable 
plasticity and can change their functions (e.g., promote 
or suppress the inflammatory responses) in response to 
factors in the microenvironment (13). Although TAMs 
in the primary tumors suppress immune reactions and 
promote tumor progression, several studies have suggested 
that activation of signaling pathways mediated by toll-
like receptor (TLR), nuclear factor-κB (NFκB), or signal 
transducer and activator of transcription 3 (STAT3) can 
prompt TAMs to be pro-inflammatory and anti-tumor 
cells (14). Therefore, it is considered that changing the pro-
metastatic phenotype of tumor-infiltrating macrophages 
is one of the attractive strategies to prevent macrophage-
promoting metastasis formation, and signaling molecules 
that regulates MAM functions can be novel therapeutic 
targets for metastatic breast cancer.
In mouse models of breast cancer pulmonary metastasis, 
MAMs express a high level of vascular endothelial growth 
factor receptor 1 (VEGFR1) compared to resident alveolar 
macrophages (8), and macrophage-restricted deletion 
of VEGR1 suppresses pulmonary metastasis of breast 
cancer cells (15). The VEGFR1 inhibition in MAMs does 
not affect MAM accumulation in the metastatic lung but 
reduces their secretion of colony-stimulating factor 1 
(CSF1) (15) that regulates phenotype of TAMs (16). These 
results thus suggest that VEGFR1-CSF1 autocrine signal 
is required for MAMs to maintain their pro-metastatic 
functions. However, signaling pathways or molecules that 
‘negatively’ regulate pro-metastatic functions of MAMs are 
largely unknown. 
A recent study published by Celus and colleagues 
in Cell Report (17) suggests that there is an intrinsic 
mechanism that suppresses metastasis promoting ability 
of MAMs. Using mouse models of spontaneous breast 
cancer metastasis, Celus et al. found that MAMs in the 
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metastatic lung expressed a high level of caveolin-1 (Cav1), 
an essential component of caveolae plasma membrane that 
mediates the internalization of cytokine receptors, and 
that genetic depletion of Cav1 significantly increased the 
number and size of lung metastatic foci. Since depletion of 
macrophages abrogated the increase in metastasis formation 
induced by Cav1 knockout, these results suggest that Cav1 
expression in MAMs restricts their pro-metastatic functions. 
Mechanistically, Celus et al. have shown that Cav1 in 
MAMs internalizes surface VEGFR1 and reduces their 
secretion of CSF1 and matrix metallopeptidase 9 (MMP9), 
which reduces angiogenesis in the metastatic tumors. 
Interestingly, Celus et al. demonstrated that Cav1 expression 
was much less in TAMs in the primary tumors compare 
with that in MAMs and that Cav1 depletion did not affect 
the growth of primary tumors or metastatic tumors in 
the liver, suggesting that Cav1 mediated suppression in 
tumor promoting macrophage function is restricted to the 
lung microenvironment. This might be partly due to the 
abundant expression of CSF2 in the lung, since monocyte-
derived macrophages cultured with CSF2 increased 
Cav1 mRNA expression. 
Although the requirement of the VEGFR1-CSF1 
autocrine loop for pro-metastatic MAM function has been 
described previously (15), this work identified, for the first 
time, Cav1 as a negative regulator of VEGFR1 induced pro-
metastatic features of MAMs. On the other hand, previous 
mouse studies indicate that MAMs in the metastatic 
lung express a high level of VEGFR1 and can promote 
metastatic tumor growth even in the Cav1 competent mice 
(8,15). Furthermore, in human breast cancer lymph node 
metastasis samples, a subset of MAMs express VEGFR1 
and the number of VEGFR1 expressing stromal cells 
are significantly higher in the metastatic tumors than 
the primary tumors (15). It might be possible that Cav1 
expression in MAMs is spatiotemporally regulated and is 
reduced in a minor population of MAM localized in a specific 
tumor area during the course of metastasis. Since VEGFR1 in 
MAM is required for metastatic tumor outgrowth (15), better 
understanding of Cav1 mediated VEGFR1 internalization in 
MAM subsets will lead to a novel strategy to improve outcome 
of metastatic breast cancer patients. However, the existence 
and biological and clinical relevance of CAV1 reduction in 
MAMs requires further analysis.
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